Clinuvel Pharmaceuticals Ltd represents values and a corporate philosophy focused on delivering innovative, science-driven therapeutic solutions. The company is committed to advancing knowledge and improving the lives of patients suffering from severe skin disorders. Clinuvel's passion for the scientific community and dedication to patient well-being is evident in their development of SCENESSE®, a groundbreaking drug for the treatment of rare genetic skin diseases. With a strong emphasis on research, development, and collaboration, Clinuvel Pharmaceuticals Ltd strives to provide innovative and effective treatments, revolutionizing the way severe skin disorders are managed.

Clinuvel Pharmaceuticals Ltd is primarily present in Australia, Europe, the United States, and other select regions globally. As a leading pharmaceutical company, Clinuvel focuses on developing and commercializing innovative therapies to treat various severe skin disorders. With a strong presence in these key markets, Clinuvel Pharmaceuticals Ltd strives to provide patients with effective and safe treatments to improve their quality of life.

Clinuvel Pharmaceuticals Ltd has achieved several significant milestones. Firstly, the company successfully obtained marketing approvals in the European Union for its product SCENESSE®, a first-line treatment for erythropoietic protoporphyria (EPP). This approval marked a major milestone for the company as it became the first-ever approved therapy for EPP patients. Additionally, Clinuvel Pharmaceuticals Ltd expanded its commercialization efforts by gaining market access in Switzerland, Australia, and the United States. Furthermore, the company demonstrated robust clinical trial data highlighting the safety and efficacy of SCENESSE®. Clinuvel's achievements in securing approvals, expanding market access and delivering substantial clinical evidence demonstrate its dedication towards improving the lives of patients with rare genetic disorders like EPP.

Clinuvel Pharmaceuticals Ltd is an Australian biopharmaceutical company specializing in the development and commercialization of therapies for genetic diseases. Founded in 1987, Clinuvel has dedicated years to research and development, focusing on photoprotection and pigmentation disorders. The company gained recognition for its flagship product, SCENESSE®, a treatment for the rare genetic disorder erythropoietic protoporphyria (EPP). Clinuvel Pharmaceuticals continues to explore potential applications of its innovative technology in various medical fields, aiming to improve the lives of patients worldwide. With a strong commitment to scientific excellence and continuous advancement, Clinuvel Pharmaceuticals Ltd remains a key player in the field of biopharmaceuticals.

The main competitors of Clinuvel Pharmaceuticals Ltd in the market are other pharmaceutical companies that specialize in developing and commercializing pharmaceutical products.

Clinuvel Pharmaceuticals Ltd is primarily active in the pharmaceutical industry.

The business model of Clinuvel Pharmaceuticals Ltd is focused on developing and commercializing pharmaceutical products for the treatment of severe genetic and skin disorders. The company specializes in innovative solutions for patients suffering from rare and ultra-rare diseases. With a strong emphasis on research and development, Clinuvel aims to improve the quality of life for individuals affected by these conditions. By leveraging its expertise in photoprotection and photorepair, Clinuvel seeks to address unmet medical needs, providing effective treatments that can significantly impact patients' lives. Clinuvel Pharmaceuticals Ltd is dedicated to advancing healthcare solutions and making a positive difference in the lives of those it serves.

Clinuvel Pharmaceuticals의 P/E 비율은 18.91입니다.

Clinuvel Pharmaceuticals의 P/S 비율은 7.06입니다.

Clinuvel Pharmaceuticals에 대한 AlleAktien 품질 점수는 6/10입니다.

Clinuvel Pharmaceuticals 매출은 95.5 백만 AUD입니다.

Clinuvel Pharmaceuticals 이익은 35.64 백만 AUD입니다.

The Australian company Clinuvel Pharmaceuticals Ltd is a biotech company specializing in developing innovative therapeutics for various skin diseases. The company focuses on researching and developing products for the treatment of rare diseases and difficult-to-treat skin conditions. Clinuvel operates three main business lines: Pharma, Cosmeceutical, and Heritage. The Pharma division of Clinuvel is the flagship of the company and includes a wide range of medical products for the treatment of various skin diseases. Clinuvel has developed an innovative drug called SCENESSE, which is approved for the treatment of patients with Erythropoietic Protoporphyria (EPP). EPP is a rare genetic disorder that causes patients to have an extremely painful sensitivity to visible light. The Cosmeceutical division of Clinuvel focuses on the development of cosmetic products that combat skin aging and keep the skin healthy and youthful. The products are typically enriched with powerful antioxidants and moisturizing agents to protect the skin and reduce the appearance of aging signs. The Heritage division of Clinuvel specializes in developing products for maintaining cultural identity and heritage preservation. These products relate to the traditions and customs of specific cultures and communities, thereby supporting the preservation of these important cultural features. Clinuvel's business model is based on a strong research and development strategy to create innovative products that provide clinical benefits and improve patients' lives. The company also has a strong focus on compliance regulations and the safety of its products. To achieve its goals, Clinuvel has established a global presence and works closely with leading experts in the pharmaceutical and biotechnology industry. The company also has strategic partnerships with non-profit organizations and other companies to expand its range of products and services. Clinuvel's goal is to provide groundbreaking solutions for the treatment of skin diseases while improving the quality of life for patients. The company aims to expand its global presence by remaining innovative and actively seeking new partnerships.

Clinuvel Pharmaceuticals은(는) 연간 1번의 배당을 통해 0.06 AUD의 배당금을 지급합니다.

Clinuvel Pharmaceuticals는 연간 1번의 배당금을 지급합니다.

Clinuvel Pharmaceuticals의 ISIN은 AU000000CUV3입니다.

Clinuvel Pharmaceuticals의 WKN은 A0JEGY입니다.

Clinuvel Pharmaceuticals의 티커는 CUV.AX입니다.

지난 12개월 동안 Clinuvel Pharmaceuticals은(는) 0.07 AUD 의 배당금을 지급했습니다. 이는 약 0.54 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Clinuvel Pharmaceuticals은(는) 0.08 AUD의 배당금을 지급할 것으로 예상됩니다.

Clinuvel Pharmaceuticals의 현재 배당 수익률은 0.54 %입니다.

Clinuvel Pharmaceuticals은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Clinuvel Pharmaceuticals은(는) 지난 13년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0.08 AUD의 배당금이 예상됩니다. 이는 배당수익률 0.63 %에 해당합니다.

Clinuvel Pharmaceuticals은 '건강' 섹터에 속합니다.

Clinuvel Pharmaceuticals의 마지막 배당금을 0.071 AUD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Clinuvel Pharmaceuticals는 0.071 AUD를 배당금으로 지급했습니다.

Clinuvel Pharmaceuticals의 배당금은 AUD에 지급됩니다.